Neha Korde
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Neha Korde as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:19 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07099391 · A Study of Dara-RVd and Teclistamab-RVd in People With Multiple MyelomaMemorial Sloan Kettering Cancer Center · recruiting · Multiple Myeloma · principal investigator
- N/ANCT04221178 · Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative RemissionMemorial Sloan Kettering Cancer Center · active not recruiting · Plasma Cell Myeloma · principal investigator
- Ph2NCT03290950 · A Study of Daratumumab in Patients With Newly Diagnosed Multiple MyelomaMemorial Sloan Kettering Cancer Center · active not recruiting · Multiple Myeloma · principal investigator
- N/ANCT03006315 · Mobile Health Device Study for Myeloma PatientsMemorial Sloan Kettering Cancer Center · completed · Multiple Myeloma, Myeloma · principal investigator
- Ph1/Ph2NCT02937571 · High Dose Carfilzomib for Newly Diagnosed MyelomaMemorial Sloan Kettering Cancer Center · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:19 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- GPRC5D-Targeted CAR T Cells for Myeloma.N Engl J Med · 2022385 citationsRCR 25.1
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.JAMA Oncol · 2015268 citationsRCR 8.1
- 168 citationsRCR 3.8
- Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.Clin Cancer Res · 2016140 citationsRCR 3.9
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.Haematologica · 2014109 citationsRCR 2.7
- 105 citationsRCR 5.2
- Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.Lancet Haematol · 202189 citationsRCR 4.8
- A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.Clin Cancer Res · 202455 citationsRCR 6.6
- 44 citationsRCR 2.0
- A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.Clin Cancer Res · 201640 citationsRCR 1.2